How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market Norbert Gerbsch, PhD Head of.

Slides:



Advertisements
Similar presentations
Life Science Cluster in Krakow
Advertisements

Intellectual Property Rights, Investment and Transfer of Technology in the Pharmaceutical Sector Patrizia Carlevaro Head of the International Aid Unit.
NASSCOM BPO STRATEGY SUMMIT 2009 BPO :: INDIAN DOMESTIC MARKET S. VENKAT KUMAR RELIANCE BPO 10 TH June 2009.
Introduction to Pharmacy Course Teacher: Asim Kumar Bepari.
PARMEE DEDHIA M.Pharm (Clinical Pharmacy), NMIMS
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Promoting E-Business among SMEs Mr. Thomas Ita Project Manager Internet/Multimedia MFG Baden-Württemberg - Agency for Media, IT and Film.
Investment opportunities in the health sector in Europe, focussing on Germany Dr. Simone Breitkopf, BPI Dr. Rudolf Schosser, Consultant.
Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences
Operational Material. 2 Presentation Outline Private Health Introduction Pharmaceutical Products Other Medical Products and Therapeutic Appliances Out-Patient.
Climate change – implications for and activities of German social partners Joint European Social Partners seminar on „The employment impact of climate.
Centre for Innovation, Technology Transfer and University Development Jagiellonian University Centre for Innovation, Technology Transfer and University.
Careers in Biomedical Engineering Technology BMET 4350 Fall 2003 Dr. Hugh Blanton.
Czech Health Care System David Marx, MD, PhD. 2 Motto: Where there is no vision, people perish. Proverbs, 29,18.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
CURRENT PHARMACEUTICAL MARKETING STRATEGY M.ABHINANDANA M.PHARM Q.A.
1 The Swiss Chemical and Pharmaceutical Industry Zurich, April 2012.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Midwest Business Group on Health National Employer Survey on Biologics/Specialty Pharmacy August 2011.
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
Challenges to Indian Multinational Cos. P. M. Kelkar 18 th March, 2006 Thorale Bajirao Peshwe Sabhagruha, Thane.
Why innovation is not happening in small scale medical equipments Industry? Subject: Innovation Management Date: 28 Feb 2010 Submitted to:Shekhar Badve.
EMERGING TRENDS AND EVOLVING OPPORTUNITIES IN PHARMACY Dr. Amrish Chandra M.Pharm., Ph.D. AMITY UNIVERSITY, NOIDA.
GDP/GNP Measuring the Economy. economic indicator  A statistic about the economy.  Allows analysis of economic performance and predictions of future.
THE STRATEGIC MANAGEMENT PROCESS [How to Analyze a Case] Dr. Ellen A. Drost Mgmt 497.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
Pharmaceutical Overview 1. Pharmaceutical Overview (1) Pharmaceuticals partially covered through various health insurance schemes Public insurance provision.
WHY Hungary? WHAT in Hungary? Gergely Mikola Chairman, British Chamber of Commerce in Hungary Director of Corporate and Regulatory Affairs in CEE, BAT.
The Pharmaceutical Industry in Turkey
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Republic of Latvia Nexia Annual Conference, Delhi, October 2008.
An-Najah National University Faculty of Engineering Industrial Engineering Department Graduation Project 1 Situational assessment for pharmaceutical sector.
EPC EDUCATION AND TRAINING – Applications for Membership of the EU Turkey - April 1987 Cyprus - July 1990 Malta - July 1990 Hungary.
Development Economics: An Overview based on Cypher and Dietz The Process of Economic Development Ch. 1.
TECHNOLOGICAL CHANGES IN GLOBAL ECONOMY PRESENTED BY: BIJAY SHARMA SECTION: A PGDM 1 st SEM.
Globalisation – Bursting Borders Anton F. Börner President Federation of German Wholesale, Foreign Trade and Services.
Macro environment analysis on pharmaceutical industry.
Leading Transformational Change China, Outsourcing and Insurance Operations | ©ReSource Pro, LLC |
Connecting European Chambers: 26th March 2015 KNOWLEDGE ALLIANCES SECTOR SKILLS ALLIANCES A PRIORITY FOR CHAMBERS.
Genexis and the Brazilian Pharmaceutical Industry
Lecture at Irkutsk State University; Mathematical Faculty Nov. 29 th -Dec.3 rd Macroeconomics, foreign trade and the European Union. Basics and Examples.
China Healthcare Consulting Inc. Creating Value for Our Clients Boston Healthcare Associates, Inc. 75 Federal Street, 9 th Floor.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
Information Technology. Information Technology? “The study, design, development, implementation, support or management of computer-based information systems,
{ Marketing Planning Analyzing the Marketing Environment and Developing a Marketing Strategy and Plan Analyzing the Marketing Environment and Developing.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
Target Analysis Group 3. Organizational Life Cycle Target has followed the typical organizational life cycle First actual store opened in 1962 in Minnesota.
Ch. 1: Business in the Economy of Hong Kong Learning Objectives Recognize the importance of business activities. Describe the role of business in Hong.
Career opportunities in medical research. Basic research.
The New Quality of Work Initiative (INQA) Demographic Change Consultant - a Training for the Consulting of Enterprises Hilke Berkels, Federal Institute.
Trade & Access to Medicines in India Centre for Trade & Development
Romanian Pharmaceutical Market – Evolutions & Perspectives September 23 rd, 2013 ZF Pharma Summit.
Marketing Environment Steered by : Dr Surabhi Goyal.
Chapter 4: ECONOMICS AND POLITICS Fundamentals of International Business Copyright © 2010 Thompson Educational Publishing, Inc
CIAT General Assembly Large Business Verification Sectorial Specialization Elvin Hedgpeth LMSB, US IRS.
Pharmaceutical Industry R&D An inside-out look at trends and career opportunities  Lots of promise but little delivered in the way of new drugs  Vastly.
DHYEYA BUSINESS SERVICES LLP Strategy Marketing Management Consultancy, IT services and Corporate Training By IIM Alumni Consultants Dhyeya Business Services.
STS Presentation. Executive Summary Huge market with high growth potential through right therapeutics areas focus  2 nd highest population in middle.
Medical Devices.
Christian Mandl, EU Coordination Policy Department Austrian Federal Economic Chamber February 2016 SME Support in Austria Small and Medium Sized Companies.
KAZAKH PHARMACEUTICAL COMPANY “MEDSERVICE PLUS” LLP 2016.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
SWOT analysis.
PHARMA CEUTICAL MANAGEMENT
The Swiss Chemical and Pharmaceutical Industry
Reforms In Insurance Sector In India
The Associated European Energy Consultants
Medical biotechnology is our topic.
WELCOME TO.
Presentation transcript:

How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market Norbert Gerbsch, PhD Head of Affairs – Biotechnology / R&D BPI - German Pharmaceutical Industry Association India

India – First Sight Charts from: Deutsche Bank Research: India´s pharmaceutical industry on course for globalisation April 2008, Population: 2006: 1.15 bn. 2030: 1.51 bn. a huge market! Growth Rates: 2008: 8.2% Above world average growing income! Drug Sales: Above par for three years growing sales! A Promising Market…

India – First Sight Chart from: Deutsche Bank Research: India´s pharmaceutical industry on course for globalisation April 2008, …for German Companies!?

India – Second Sight INDIAGERMANY Population1,122 mio82 mio GDP, 2007 [EUR] 684 bn2,423 bn Growth [%] GDP per capita 2007 [EUR] 64229,450 Sales of pharmaceuticals 2007 [EUR] 10 bn26,8 bn Sales covered by Health Insurance [%] 20 (4)80 (99) Sales of pharmaceuticals per year and capita, 2007 [EUR] „Middle class“ spending per year and capita appr. 42.5? Number of companies20,0001,032 Number of pharmaceutical products 70,00060,000 Employees500,000127,000

Consequences India is a huge and promising market, but… compared to Germany: -different volume -different pricing levels -different spending per capita -different structure (directly payed by customer vs. health insurance) -different distribution systems -similar company structure (small to medium sized, privately owned) …more differences than similarities!

-for specialty care products, which are not yet available in India -which are patent protected or protected otherwise (production technologies) -Roundabout 20 German companies have established a presence in India -needs very careful analysis of the Indian markets -local partners which know the situation in India -marketing, reimbursement, distribution, authorities, Chances / Challenges

Market Access - Challenges to obtain valid information for market evaluation / planning to obtain sustainable information about government plans to develop the health system – mid to long term to find partners in India product protection by patents Infrastructure payment transactions different time frames high customs for imported goods cultural challenges

Networking in the German Pharmaceutical Industry How to Use an Existing Platform BPI - The German Pharmaceutical Industry Association - Established in

The German Pharmaceutical Industry Association (BPI) Established in 1951, with 57 years of experience in the development, regulatory approval and marketing of pharmaceuticals as well as political lobbying An alliance of about 260 members, representing a wide spectrum of the pharmaceutical industry –Small Enterprises –Multinational Corporations –Contract Manufacturers –Contract Research Organizations (CROs) –Attorneys specializing in pharmaceutical law –Consultants An ideal information and communication platform

The Staff of the BPI The BPI covers many diverse fields of activities, which can be summarized in six central core competencies: –Medicine and Pharmacy –Biotechnology / R & D –Politics –Law –Self Medication –Press / Public Relations At BPI, experts from various disciplines work closely together – pharmacists, physicians, economists, lawyers, etc.

Support / BPI Cooperation platform The BPI Cooperation Platform on the BPI homepage offers –Members and –Non-members the opportunity to find business partners in various fields or to actively offer themselves as partners. Offers are posted anonymously, with the BPI acting as a intermediary between the two partners Might be useful to overcome some of the access barriers mentioned

Thank you for your attention!